| # | Title | Journal | Year | Citations |
|---|
| 1 | Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy | JAMA Oncology | 2018 | 567 |
| 2 | Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers | PLoS ONE | 2015 | 390 |
| 3 | Metabolic phenotype of bladder cancer | Cancer Treatment Reviews | 2016 | 201 |
| 4 | PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises | Cancer Treatment Reviews | 2015 | 161 |
| 5 | Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC | Journal of the National Cancer Institute | 2017 | 128 |
| 6 | Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma | Cancer Immunology, Immunotherapy | 2013 | 110 |
| 7 | HER2 loss in HER2‐positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research | International Journal of Cancer | 2016 | 94 |
| 8 | Patients’ perception of chemotherapy side effects: Expectations, doctor-patient communication and impact on quality of life - An Italian survey | European Journal of Cancer Care | 2017 | 91 |
| 9 | BAP1,PBRM1andSETD2in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies | Expert Review of Molecular Diagnostics | 2015 | 78 |
| 10 | Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study | European Urology | 2015 | 73 |
| 11 | Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors | Annals of Surgical Oncology | 2015 | 72 |
| 12 | Metabolic alterations in renal cell carcinoma | Cancer Treatment Reviews | 2015 | 71 |
| 13 | PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around | Cancers | 2019 | 71 |
| 14 | Emerging concepts on drug resistance in bladder cancer: Implications for future strategies | Critical Reviews in Oncology/Hematology | 2015 | 64 |
| 15 | Prostate cancer heterogeneity: Discovering novel molecular targets for therapy | Cancer Treatment Reviews | 2017 | 64 |
| 16 | Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort | European Journal of Cancer | 2013 | 60 |
| 17 | Role of STAT3 pathway in genitourinary tumors | Future Science OA | 2015 | 58 |
| 18 | Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma | Journal of Urology | 2015 | 58 |
| 19 | Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib ofEGFRmutant advanced lung adenocarcinoma | Oncotarget | 2015 | 58 |
| 20 | Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer | Critical Reviews in Oncology/Hematology | 2015 | 54 |
| 21 | High-affinity monomeric 67-kd laminin receptors and prognosis in pancreatic endocrine tumours | Critical Reviews in Oncology/Hematology | 1997 | 52 |
| 22 | CXC and CC Chemokines as Angiogenic Modulators in Nonhaematological Tumors | BioMed Research International | 2014 | 51 |
| 23 | Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives | Critical Reviews in Oncology/Hematology | 2018 | 50 |
| 24 | Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy | Targeted Oncology | 2015 | 49 |
| 25 | AR-V7 and prostate cancer: The watershed for treatment selection? | Cancer Treatment Reviews | 2016 | 49 |
| 26 | Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: An up-to-date review and meta-analysis of clinical trials | International Journal of Cancer | 2015 | 47 |
| 27 | The prospect of precision therapy for renal cell carcinoma | Cancer Treatment Reviews | 2016 | 46 |
| 28 | New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors | Expert Opinion on Drug Metabolism and Toxicology | 2016 | 46 |
| 29 | Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting | Oncologist | 2016 | 45 |
| 30 | PFS to predict long-term OS after first-line treatment for advanced renal cell carcinoma (aRCC): Correlation and power analysis of randomized trials (RCT). | Journal of Clinical Oncology | 2012 | 45 |
| 31 | Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer | Expert Opinion on Investigational Drugs | 2015 | 43 |
| 32 | MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy | Annals of Translational Medicine | 2017 | 42 |
| 33 | Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study | Clinical Lung Cancer | 2018 | 41 |
| 34 | Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations | Clinical Lung Cancer | 2019 | 40 |
| 35 | Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets | Pathology | 2020 | 35 |
| 36 | High mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugs | BMC Cancer | 2014 | 34 |
| 37 | Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I nonsmall cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung | International Journal of Cancer | 2005 | 33 |
| 38 | Neoadjuvant chemotherapy in triple‐negative breast cancer: A multicentric retrospective observational study in real‐life setting | Journal of Cellular Physiology | 2018 | 33 |
| 39 | Pancreatic Cancer: Systemic Combination Therapies for a Heterogeneous Disease | Current Pharmaceutical Design | 2014 | 33 |
| 40 | Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world | Gastric Cancer | 2017 | 32 |
| 41 | Sequential use of new agents (NAs) after docetaxel (DOC) first line in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A pooled-analysis of the published studies. | Journal of Clinical Oncology | 2015 | 32 |
| 42 | Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer | Oncotarget | 2014 | 32 |
| 43 | Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers | Future Oncology | 2016 | 31 |
| 44 | Targeting the epidermal growth factor receptor in solid tumors: focus on safety | Expert Opinion on Drug Safety | 2014 | 30 |
| 45 | The origin of prostate metastases: emerging insights | Cancer and Metastasis Reviews | 2015 | 30 |
| 46 | Tracking MET de-addiction in lung cancer: A road towards the oncogenic target | Cancer Treatment Reviews | 2017 | 29 |
| 47 | Tp53 and its potential therapeutic role as a target in bladder cancer | Expert Opinion on Therapeutic Targets | 2017 | 28 |
| 48 | Factors Influencing Physical Activity in Cancer Patients During Oncological Treatments: A Qualitative Study | Integrative Cancer Therapies | 2020 | 28 |
| 49 | Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside | Cancer and Metastasis Reviews | 2014 | 27 |
| 50 | Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy | Oncologist | 2017 | 27 |
